Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2437206 | 0.88 | MEN1 (0.57) | MEN1TP53KMT2AAKR1C3CYP2C9 | |
| SCHEMBL2688487 | 0.80 | MEN1 (0.52) | MEN1TP53KMT2AAKR1C3CYP2C9 | |
| SCHEMBL2445342 | 0.80 | MEN1 (0.52) | MEN1TP53KMT2AAKR1C3CYP2C9 | |
| SCHEMBL2445340 | 0.80 | MEN1 (0.52) | MEN1TP53KMT2AAKR1C3CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL29191950 | 0.78 | CHRM2 (0.44) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL1700180 | 0.77 | L3MBTL1 (0.39) | SMN1; SMN2DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL21645222 | 0.77 | L3MBTL1 (0.39) | SMN1; SMN2DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL9066267 | 0.77 | CA2 (0.48) | MEN1TP53KMT2AAKR1C3CYP2C9 | |
| SCHEMBL1136825 | 0.76 | GNAI3 (0.46) | MEN1TP53KMT2ADPP4 | |
| Trifluoroacetic Acid SCHEMBL23535368 | 0.76 | DPP7 (0.41) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | MEN1 3865/4885TP53 519/4885KMT2A 2686/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | MEN1 3716/4885TP53 255/4885KMT2A 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.